Recent articles for private investors with a focus on dividend announcements
Laird increases its 2015 interim dividend by 3%
Good first half performance in line with expectations
Rolls Royce increases its 2015 interim 'payment to shareholders' by 3%
Warren East, Chief Executive, said: "Despite the disappointment of our recent update, our second half outlook remains positive and full-year guidance for revenue, profit and cash issued on July 6th remains unchanged. The continued growth in our order book demonstrates the long-term demand for our innovative products and services, and underpins my confidence in the fundamental strength of our business."
Schroders increases its 2015 interim dividend by 21%
Profit before tax and exceptional items up 17 per cent. to £305.7 million (H1 2014: £261.5 million)
Money supermarket increses its 2015 interim dividend by 10%
Insurance revenues up 8% with car insurance premiums starting to show a marginal increase.
Countrywide maintains its 2015 interim dividend at last years level
Group income grew to £338.6 million, however, a difficult UK housing market led to £41.0 million of EBITDA versus £45.0 million in the same period last year
Weir group holds its 2015 interim dividend at last years level
Dividend The Board has decided to hold the interim dividend flat at 15.0p (2014: 15.0p). The interim dividend will be paid on 6 November 2015 to shareholders on the register on 9 October 2015.
GlaxoSmithKline 2015 Q2 results
Summary
·
Group sales +7% CER on a reported basis and +2% CER pro-forma
-
Pharmaceuticals £3.5 billion, -6% (+2% pro-forma); Vaccines £0.8 billion, +11% (-5% pro-forma); Consumer Healthcare £1.5 billion, +51% (+6% pro-forma)
-
New Pharmaceutical and Vaccine sales of £446 million in Q2
·
Q2 core EPS of 17.3p, flat in CER terms
-
EPS reflects dilution of Novartis transaction, ongoing pricing pressure partly offset by cost reductions
-
Integration of new Consumer and Vaccine businesses on track
-
On track to deliver targeted annual cost savings of £3 billion from all restructuring programmes
·
Total Q2 EPS of 3.1p and H1 EPS of 170.7p
-
Reflects phasing of pre-tax transaction gains and accelerated restructuring charges
·
2015 earnings guidance and 2016 outlook reiterated
-
Expect 2015 core EPS to decline at a high teen percentage rate (CER)
-
2016 core EPS percentage growth expected to reach double digits (CER)
·
Q2 dividend of 19p declared
-
Continued expectation for full year dividend of 80p
·
R&D innovation with significant potential to drive long-term Group performance
-
Progress of new respiratory portfolio continues with positive FDA AdCom recommendation for Nucala and regulatory filing for approval in Japan
-
Positive CHMP decision received for Mosquirix
-
Group has ~40 NMEs (drugs and vaccines) in Phase II/III clinical development, primarily focused on HIV, Oncology, Vaccines, Cardiovascular, Immuno-inflammation and Respiratory diseases
-
New data and prospects for advanced/early-stage pipeline to be reviewed at R&D event in November
Jupiter fund management increases its 2015 interim dividend by 8.1%
Continued organic flow growth from our core mutual fund franchise, with net mutual fund inflows of £1.4bn
National Express increases its 2015 interim dividend by 10%
Half Year Results for the six months ended 30 June 2015
St James's place increases its 2015 interim dividend by 20%
New Investment and Funds under Management
Law debenture Group 2015 interim results
HALF YEARLY REPORT FOR THE SIX MONTHS TO 30 JUNE 2015 (unaudited)
Capital and Counties 2015 interim results
Highlights Driving value creation through a clear and focused strategy
Pace passes on its 2015 interim dividend due to Arris merger
Solid H1 2015: Gross margin up 1.6ppt to 23.2%, operating margin up 1.6ppt to 10.9% and adjusted basic EPS up 11.4% to 28.4c. Strong H2 2015 anticipated and the proposed combination with ARRIS Group is progressing in-line with expectations.
5401-5450 of 8143
